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Objective. To compare the urate-lowering efficacy and the 
safety of febuxostat, allopurinol and placebo in Korean pa-
tients with gout for 4 weeks.
Methods. Subjects (n=182) with gout were randomized to 
febuxostat (40, 80, 120 mg), allopurinol 300 mg, or placebo 
group. The primary end point was the proportion of sub-
jects whose serum urate concentration fell to less than 6.0 
mg/dL after the 4-week treatment. 
Results. The primary end point was reached at 25.7%, 
80.0% and 83.3% of patients receiving 40, 80 and 120 mg 
of febuxostat, respectively, 58.3% of those receiving 300 mg 
of allopurinol and none of the placebo (p＜0.001: each fe-
buxostat dose or allopurinol group versus placebo group, 
p=0.0484 and p=0.0196: febuxostat 80 and 120 mg compared 
with allopurinol, respectively). The number and proportion 
of subjects who developed adverse events (AEs) were 13 sub-
jects (37%), 14 (39%) and 18 (50%) in the febuxostat of 40, 
80 and 120 mg group, respectively, 21 (57%) in the allopur-
inol 300 mg group and 17 (46%) in the placebo group. No 
statistically significant differences in the incidence rates of 
adverse events were observed between the groups. There 
was no significant difference in gout flare-up incidence.
Conclusion. Febuxostat, 80 mg or 120 mg, was more effec-
tive than allopurinol (300 mg) or placebo, when lowering 
the serum urate. The safety of febuxostat and allopurinol 
was comparable.
Key Words. Gout, Febuxostat, Urate-lowering efficacy, 
Korean patients
Introduction
 Febuxostat is a new uric acid synthesis inhibitor. It is a 2-ar-
ylthiazole derivative, which was chemically engineered, as a 
novel xanthine oxidase/xanthine dehydrogenase (XO) inhibitor. 
Febuxostat is being used for the management of hyperuricemia 
in patients with gout (1-3), and is already approved for market-
ing in major countries including EU, USA and Japan.
 For over 30 years, allopurinol is the only uric acid synthesis 
inhibitor that is being used for hyperuricemia and gout. Uric 
acid is the last product of purine metabolism, by a process cata-
lyzed by XO, through which, subsequent intermediate products 
are generated from hypoxanthine to xanthine, and finally to uric 
acid. Allopurinol, whose chemical structure is similar to that of 
purine, acts as an inhibitor of xanthine oxidase. Oxipurinol, a 
major metabolite of allopurinol, also inhibits other enzymes in 
the process of purine metabolism (4,5). Oxipurinol is mainly ex-
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creted via the urine and its excretion is delayed in patient with 
renal dysfunction. Continued high serum level of oxipurinol in 
patients with renal problems is worrisome (5). Febuxostat is a 
new uric acid synthesis inhibitor, which has a totally different 
chemical structure from that of allopurinol. It selectively inhibits 
XO, without acting on the other major enzymes that are related 
to purine metabolism. It has been confirmed to be a potent se-
lective xanthine oxidase/xanthine dehydrogenase (XO) inhibitor 
in vitro and have strong effects on lowering the serum and urine 
uric acid concentrations in animals, such as rats and chimpan-
zees (6,7). Several randomized controlled clinical trials (RCTs) 
have shown febuxostat’s (in daily doses from 80 to 240 mg) 
superiority in urate-lowering efficacy, when compared to that 
of placebo or allopurinol at 300 mg daily. Moreover, febuxostat 
was more efficacious than allopurinol and was equally safe for 
subjects with hyperuricemia and gout complicated by mild and 
moderate renal impairment (8-11). The small number of severe 
cardiovascular (CV) AEs, was encountered in febuxo-
stat/allopurinol comparative RCTs. However safety of febuxo-
stat and allopurinol, including CV safety, was comparable at 
doses of 40 mg or 80 mg of febuxostat (8).
 In a phase II study involving gout patients, the proportion 
of subjects achieving a serum urate concentration of ＜6.0 
mg/dL, after 4 weeks of treatment, with febuxostat 40 mg QD, 
febuxostat 80 mg QD and febuxostat 120 mg QD were 56%, 
76% and 94%, respectively (12). The mean serum uric acid 
reduction from baseline at day 28 was 2% in the placebo 
group, 37% in the 40 mg febuxostat group, 44% in the 80 
mg febuxostat group and 59% in the 120 mg febuxostat group. 
The difference in urate level reduction was statistically sig-
nificant between the placebo group and each of the febuxostat 
treatment groups (febuxostat 40 mg, 80 mg and 120 mg). 
These previous results suggested that a 4-week trial is accept-
able in demonstrating the urate lowering efficacy of 
febuxostat.
 This was a randomized, multi-centered, double-blinded, allo-
purinol-controlled, placebo-controlled study, which is under-
taken to evaluate the urate-lowering effect of febuxostat in the 
Korean population with hyperuricemia and gout.
Materials and Methods
Study population
 Subjects with the age of 18 to 85 years, with a diagnosis 
of gout (based on the preliminary criteria of the American 
College of Rheumatology for acute arthritis of gout (13)) 
were enrolled in the study. Serum uric acid of ≥8.0 mg/dL 
and serum creatinine of ≤1.5 mg/dL were eligible for the 
study. 
 Exclusion criteria included; subjects with hypersensitivity to 
allopurinol, thiazide diuretic therapy, aspirin ＞325 mg/day, 
prednisolone ＞10 mg/day, alcohol intake ≥14 drinks/week, 
other urate-lowering therapy, and hepatic dysfunction (both 
alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) ＞1.5 times the upper limit of normal).
Study method
 This study was conducted at 10 centers in Korea and was 
approved from the institutional review boards of each re-
spective institution based on the Declaration of Helsinki. All 
subjects gave written informed consent.
 Subjects that passed the screening evaluation were then ran-
domly assigned to one of the five treatment regimens; febuxo-
stat 40 mg, 80 mg, 120 mg, placebo or allopurinol 300 mg 
QD based on their serum urate level at baseline (1) ≥8 
mg/dL, ＜9 mg/dL, 2) ≥9 mg/dL, ＜10 mg/dL, 3) ≥10 
mg/dL). The stratified randomization was used to keep the 
balance of serum urate concentration between groups and 
done by the central coordinator to maintain the blindness. The 
patient visiting schedule was as follows; day -14 or day -1 
screening visit (day -14 for subjects taking allopurionol or ur-
icosuric agents prior to this study, or Day -1 for subjects not 
receiving allopurionol or uricosuric agents), day -1 visit, day 
1 visit and the 28-day treatment period. Colchicine 0.6 mg 
QD was given to minimize the risk of gout flare-ups, acute 
gout response manifesting red, hot or swollen joint with pain, 
during the washout/run-in period, and during the double blind 
study period. The medication which could impact on the se-
rum urate concentration and interact with the study medication 
was prohibited; chronic use (＞100 consecutive days) of 
NSAIDs, salicylate-containing medication, probenecid, benz-
bromarone, thiazide diuretics, predisone, azathioprine, mercap-
topurine, dicumarol, cyclophospamide, trimethoprim-sulfame-
thoxazole and so on. Low dose aspirin (≤325 mg/day) and 
acetaminophen were allowed as required.
Efficacy endpoint
 The primary end point was the proportion of subjects whose 
serum urate concentration fell to less than 6.0 mg/dL after 4 
weeks of treatment. The secondary end point was the percent 
reductions in serum urate levels from the baseline to the end 
of the study (day 28).
Demographic information and medical history
 All data were collected from the patients regarding body 
mass index (BMI), alcohol use and coexisting conditions, ac-
cording to each treatment group. 
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Figure 1. Flow chart of the patient allocation.
Statistical analysis
 Efficacy analysis was based on the intention to treat (ITT) 
population. The last-observation-carried-forward (LOCF) im-
putation method was used for the missing data. The primary 
endpoint, the proportion of the subjects, whose serum urate 
concentration that fell to less than 6.0 mg/dL after the 4-week 
treatment, was compared across the febuxostat groups, the 
placebo group and the allopurinol group using a chi-square 
or fisher’s exact test. The three febuxostat treatment groups 
(40 mg QD, 80 mg QD, and 120 mg QD) and the placebo 
treatment group were compared using the Bonferroni multiple 
comparison. The percent reductions in serum urate levels 
from the baseline at each visit, within each treatment group, 
were analyzed by analysis of covariance (ANOVA) and re-
peated measure ANCOVA was used for the comparison be-
tween each of the treatment group. 
 In compliance with the Medical Dictionary for Regulatory 
Activities (MedDRA) coding dictionary, the number of sub-
jects, who experienced treatment-emergent adverse events 
(TEAEs) and the percentages, were presented. Between- 
groups comparisons of TEAE incidence were conducted, using 
a chi-square test or Fisher’s exact test. The frequency of sub-
jects requiring treatment of gout flare-up was compared 
among the treatment groups, using a chi-square test or 
Fisher’s exact test.
 Baseline demographics were compared by ANOVA or 
Kruskal Wallis test for continuous variables and by chi- 
square test or Fisher’s exact test for categorical variables.
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Table 1. Baseline characteristics of the gout patients according to the treatment groups
Characteristic
Febuxostat
40 mg (n=35)
Febuxostat
80 mg (n=36)
Febuxostat
120 mg (n=36)
Allopurinol
300 mg (n=37)
Placebo
(n=37)
p-value
Age (mean±SD years)
BMI
Alcohol use
Tobacco use
Coexisting conditions
　Diabetes mellitus
　Dyslipidemia‡
　Hypertension
Baseline serum creatinine
Baseline serum urate concentration
 (mean±SD mg/dL)
　≥8 mg/dL, ＜9 mg/dL
　≥9 mg/dL, ＜10 mg/dL
　≥10 mg/dL
Previous urate-lowering therapy
　Allopurinol
　Benzbromarone
49.6±11.9
26.3±3.5
20 (57.1)
9 (25.7)
1 (2.9)
4 (11.4)
11 (31.4)
1.2±0.1
9.7±1.1
9 (25.7)
16 (45.7)
10 (28.6)
18 (51.4)
2 (2.7)
48.9±12.3
25.1±2.8
24 (66.7)
13 (36.1)
0 (0.0)
3 (8.3)
9 (25.0)
1.2±0.2
9.7±1.1
10 (27.8)
16 (44.4)
10 (27.8)
21 (58.3)
3 (8.3)
51.2±9.9
25.8±2.1
28 (77.8)
12 (33.3)
0 (0.0)
5 (13.9)
8 (22.2)
1.2±0.1
9.5±1.0
10 (27.8)
16 (44.4)
10 (27.8)
19 (52.7)
3 (8.3)
48.6±11.8
25.7±3.3
26 (70.3)
17 (46.0)
2 (5.4)
5 (13.5)
18 (48.7)
1.2±0.1
9.6±1.0
10 (27.0)
16 (43.2)
11 (29.7)
21 (56.8)
0 (0.0)
51.8±12.4
25.7±3.1
28 (75.7)
14 (37.8)
1 (2.7)
10 (27.0)
12 (32.4)
1.2±0.1
9.8±1.2
11 (29.7)
16 (43.2)
10 (27.0)
19 (51.6)
3 (8.1)
0.6978*
0.5421*
0.3419†
0.2344†
0.9934†
0.3081*
0.8230*
1.0000†
0.9678†
BMI: body mass index. *p-value by ANOVA or Kruscal Wallis test, †p-value by Fisher’s exact test or chi-square test, ‡including 
hypercholesterolemia and hypertriglyceridemia.
Figure 2. The proportions of subjects with serum urate levels 
falling to ＜6.0 mg/dL after the 4-week treatment. *p＜0.0001 vs. 
placebo, Febuxostat 40 mg, 80 mg, 120 mg vs. allopurinol, 
p=0.0054, 0.0484, 0.0196 respectively. p-value by Fisher’s exact 
test or chi-square test.
Results
Subject demographics and disposition
 Of the 247 subjects screened, 182 were randomly assigned 
to the different treatment groups (Figure 1). All subjects were 
male. The mean age (±SD) was 50.0 (±11.6) years old. No 
statistically significant difference was found in the age dis-
tribution between the groups (p=0.6978). There was also no 
statistically significant difference in BMI, smoking, drinking 
history and coexisting conditions between the groups. There 
were no significant differences across the treatment groups in 
the baseline concentration of serum uric acid (Table 1). 
 Withdrawal rates were similar in all the five groups. One 
subject randomized to febuxostat 40 mg was excluded from 
the ITT efficacy analysis, due to the consent withdrawal prior 
of starting the medication regimen. Two subjects (1 each in 
the febuxostat 40 mg and allopurinol 300 mg), who did not 
have evaluable results of the serum urate level, were excluded 
from the ITT efficacy analysis.
Efficacy analyses
 Primary efficacy endpoint: The proportion of subjects with se-
rum urate concentration falling to less than 6.0 mg/dL, after 
the 4-week treatment, was 25.7% for patients receiving 40 mg 
of febuxostat, 80.0% for those receiving 80 mg of febuxostat, 
83.3% for those receiving 120 mg of febuxostat, and 58.3% 
for these receiving 300 mg of allopurinol (p＜0.001 when 
comparing each febuxostat or allopurinol group with the pla-
cebo group).
 Using the allopurinol 300 mg group as the reference, for 
which the febuxostat 40 mg showed lower response rate 
(p=0.0054). However the febuxostat 80 mg and febuxostat 120 
mg groups showed higher response rates (p=0.0484, p=0.0196 
respectively, Figure 2). 
 Secondary efficacy endpoint: The percent reduction in the se-
rum urate levels from the baseline at the end of the study (day 
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Table 2. Percent reduction of serum urate concentration from baseline at final visit - ITT population
Treatment group Mean±SD (mg/dL) p-value (vs. placebo) p-value (vs. allopurinol)
Febuxostat 40 mg (N=35)
Febuxostat 80 mg (N=35)
Febuxostat 120 mg (N=36)
Allopurinol 300 mg (N=36)
Placebo (N=37)
Baseline
Day 14
Day 28
Percent reduction (%)
Baseline
Day 14
Day 28
Percent reduction (%)
Baseline
Day 14
Day 28
Percent reduction (%)
Baseline
Day 14
Day 28
Percent reduction (%)
Baseline
Day 14
Day 28
Percent reduction (%)
9.7±1.1
6.4±1.0
6.5±1.2
−32.4±12.4
9.7±1.1
4.7±0.9
4.9±1.5
−49.0±12.8
9.5±1.0
4.3±1.8
4.2±1.9
−55.7±20.4
9.6±1.0
5.8±1.3
5.8±1.5
−40.4±13.5
9.8±1.2
9.8±1.5
9.8±1.5
0.9±13.6
＜.0001
＜.0001
＜.0001
＜.0001
−
0.0116
0.0070
＜.0004
−
−
p-value by t-test. ITT: intention to treat.
28) were analyzed. The percent reduction in the serum urate 
concentration from the baseline at 28 days were 32.4±12.4% 
in patients receiving 40 mg of febuxostat, 49.0±12.8% in 
those receiving 80 mg of febuxostat, 55.7±20.4% in those re-
ceiving 120 mg of febuxostat, 40.4±13.5% in those receiving 
300 mg of allopurinol and 0.9±13.6% in those receiving pla-
cebo (p＜0.001 by t-test when comparing each febuxostat or 
allopurinol group with the placebo group) (Table 2). As the 
dose of the febuxostat being administered increased, the per-
cent reduction in the serum urate concentration tended to be 
increased, but it was not statistically significant. 
 Adverse events (AEs): The incidence of AEs was similar 
among the five treatment groups (Table 3). AEs occurring in 
＞5% of the subjects, in each treatment group, are listed in 
Table 3. The majority of AEs were mild or moderate in 
severity. The frequency of abnormal liver function tests (≥2.0 
times the upper limits of normal) between the groups were 
similar (Table 4).
 The results of the laboratory test, vital signs and electro-
cardiogram did not show any significant difference and the 
most of subjects showed the finding within the normal range.
 There were 4 cases in which the patients were withdrawn, 
due to adverse events.
 Serious adverse events: One of three SAEs, acute pancreatitis, 
judged as related to the investigational drug occurred in the 
allopurinol 300 mg group. The other two cases, renal cell car-
cinoma and coronary artery disease, were considered as un-
likely related to the investigational drug. 
 Gout flare-ups: Gout flare-up appeared in 1 subject (2.86%) 
in the febuxostat 40 mg group, 3 subjects (8.33%) in the fe-
buxostat 120 mg group, 2 subjects (5.41%) in the allopurinol 
300 mg group and 1 subject (2.70%) in the placebo group. 
No subject developed gout flare-up in the febuxostat 80 mg 
group. There was no significant difference in the incidence of 
gout flare-up between each treatment group and the placebo 
group. Dose-dependent gout flare-ups did not occur in the fe-
buxostat group (Figure 3).
Discussion 
 Febuxostat is a novel non-purine, selective inhibitor of xan-
thine oxidase. This drug was developed to treat hyperuricemia 
and gout (4-6). Febuxostat is being used for the management 
of hyperuricemia in patients with gout and has already been 
approved for marketing in major countries, including EU, 
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Table 3. Adverse events occurring ＞5% of subjects according to each treatment group
Febuxostat
40 mg (n=35)
Febuxostat
80 mg (n=36)
Febuxostat
120 mg (n=36)
Allopurinol
300 mg (n=37)
Placebo
(n=37)
p-value
Number of subjects with treatment emergent
 adverse events (TEAEs, %)
　Arthralgia
　Diarrhea
　Urticaria
　Alanine aminotransferase (ALT) increased*
　Aspartate aminotransferase (AST) increased†
　Blood bilirubin increased‡
　Hypertriglyceridaemia§
Number of subjects with TEAEs related to drug
Number of subjects with TEAEs
 leading to withdrawal
Number of subjects with serious TEAEs 
　Coronary artery disease
　Acute pancreatitis 
　Renal cell carcinoma stage I
13 (37.1)
0
2 (5.7)
0
7 (20.0)
4 (11.4)
0
2 (5.7)
7 (20.0)
0
0
14 (38.9)
2 (5.6)
2 (5.6)
1 (2.8)
3 (8.3)
3 (8.3)
0
1 (2.8)
7 (19.4)
1 (2.8)
1 (2.8)
1 (2.8)
18 (50.0)
2 (5.6)
0
0
5 (13.9)
3 (8.3)
0
1 (2.8)
7 (19.4)
0
0
21 (56.78)
0
1 (2.7)
0
4 (10.8)
4 (10.8)
2 (5.4)
4 (10.8)
13 (35.1)
2 (5.4)
1 (2.7)
1 (2.7)
1 (2.7)
17 (46.0)
0
1 (2.7)
2 (5.4)
1 (2.7)
1 (2.7)
0
2 (5.4)
6 (16.2)
1 (2.7)
0
NS
NS
NS
NS
p-value, febuxostat or allopurinol vs. placebo. p-value by chi-square or Fisher’s exact test. NS: not significant, *ALT increase above 
the upper normal limit, 43 IU/L, †AST increase above the upper normal limit, 38 IU/L, ‡Bilirubin increase above the upper normal 
limit, 1.2 mg/dL, §Triglycerides increase above 200 mg/dL.
Table 4. Liver function test abnormalities
Febuxostat
40 mg (n=35)
Febuxostat
80 mg (n=36)
Febuxostat
120 mg (n=36)
Allopurinol
300 mg (n=37)
Placebo
(n=37)
p-value
ALT ≥2.0 times the ULN
AST ≥2.0 times the ULN
1 (2.9)
0
1 (2.8)
0
1 (2.8)
0
3 (8.1)
1 (2.7)
0
0
NS
NS
Values are the number of patients (%). ALT: alanine aminotransferase, AST: aspartate aminotransferase, ULN: upper limit of normal. 
p-value, febuxostat or allopurinol vs. placebo, NS: not significant.
Figure 3. The frequency of subjects with gout flare-up. There 
were no significant differences in the incidence of gout flare-up 
between the groups during the treatment period (p＞0.05).
USA and Japan. This clinical study was conducted for the pur-
pose of confirming the safety and efficacy of febuxostat in 
Korean patients with gout.
 In line with previous RCT study (12), the urate lowering effi-
cacy of febuxostat at daily dose of 40 mg was higher than 
that of the placebo. Compared to the allopurinol 300 mg group 
as a reference, the febuxostat 80 mg and febuxostat 120 mg 
groups showed better urate lowering efficacy (p=0.0484, 
p=0.0196). The efficacy rate was lower in the febuxostat 40 
mg group than the other groups, upon the proportion of sub-
jects with the serum urate levels falling below 6.0 mg/dL. 
However the percent reduction of serum urate with febuxostat 
40 mg group was about 32.4%.
 The meaningful effectiveness rapidly appeared at week 2 and 
was maintained until week 4 of treatment.
 In this study, allopurinol 300 mg was chosen for the refer-
ence since it was thought to be used by most subjects eligible 
for the study. 
 As in the previous study (12), the proportion of subjects 
whose serum urate concentration decreased to less than 6.0 
mg/dl, after a 4-week treatment, were 80.0% of patients re-
ceiving 80 mg of febuxostat and 83.3% of those receiving 120 
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mg of febuxostat in the present study. This result suggests the 
recommendation that if serum uric acid concentration does not 
decrease to less than 6 mg/dL, after two weeks of 40 mg of 
febuxostat given daily, the dosage can be increased to 80 mg 
once daily. In the subgroup analysis of patients with uric acid, 
of more than 10 mg/dL, the response rate tended to increase 
with higher dose of febuxostat (data not shown).
 According to the prior report, dosage adjustments were not 
needed in the elderly patients or patients with mild or moder-
ate renal or hepatic impairment (14).
 The overall incidence of treatment related AEs occurring in 
＞5% of subjects in each group was similar for all the treat-
ment groups, and most were mild to moderate in severity. The 
rate of discontinuation due to AEs was also similar for all 
treatment groups. A case of coronary artery disease was re-
ported in the 80 mg febuxostat group. This patient had a fam-
ily history of ischemic heart disease and suffered from 
hypertension. Although he had no symptoms of coronary ar-
tery disease, he was evaluated by routine coronary CT on the 
14th day of febuxostat. He was diagnosed with coronary 3 
vessel disease and underwent heart bypass surgery. There was 
no complications after the surgery and he was discharged 
from the hospital one week later. The investigators assessed 
that this was unlikely related to the investigational drug.
 In clinical practice, gout and hyperuricemia are strongly as-
sociated with cardiovascular disease and its risk factors. In 
this clinical trial, 45.6% of the enrolled subjects had risk fac-
tors for cardiovascular diseases. In addition, no significant dif-
ference between the treatment groups was observed in terms 
of cardiovascular AEs. Although AEs of increased ALT and 
AST were more frequent in the febuxostat and allopurinol 
groups than in the placebo group, the incidence rates in each 
group were comparable.
 There was no significant difference in gout flare-up in-
cidences between febuxostat or allopurinol groups and the pla-
cebo group. Dose-dependent gout flare-ups did not occur in 
the febuxostat group.
 Allopurinol can cause a rare but fatal adverse event, such 
as allopurinol hypersensitivity and toxic epidermal necrolysis 
(15-17). Benzbromarone is also limitedly used because of its 
adverse effects of hepatotoxicity (15). 
 Febuxostat may be an alternative for patients with gout who 
are unable to take allopurinol due to hypersensitivity, intoler-
ance, or lack of efficacy (3). Although the treatment period 
is as short as 28 days, the previous study (10) confirms that 
effectiveness appeared at week 2 and there were no sig-
nificant differences for the reduction of serum urate levels 
among each visit after then. However, further study of long 
term treatment with febuxostat compared with allopurinol 
could ensure the effectiveness and safety of febuxostat in 
Korean patients.
Conclusion
 Febuxostat is proven to lower serum urate levels in Korean 
patients with gout and the effectiveness of febuxostat 80 mg 
and 120 mg was superior to that of allopurinol. Febuxostat 
given daily at 40 mg, 80 mg and 120 mg was safe and well- 
tolerated. Febuxostat can be a new treatment option for pa-
tients with hyperuricemia and gout. 
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